Browse News
Filter News
Found 1,389 articles
-
CAR T-Cell Therapy Market to Rise at a Revenue of US$ 22.2 Billion By 2032
4/23/2024
The global CAR T-Cell Therapy Market is projected to reach USD 22.2 billion by 2032 up from USD 2.1 billion in 2023, at a CAGR of 30% from 2024-2032.
-
From gene-corrected cell therapies to a new CAR-T, the cell and gene therapy space looks to expand its reach into the market.
-
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033
4/12/2024
According to Nova One Advisor, the U.S. Biotechnology market size was estimated at USD 552.49 billion in 2023
-
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
4/11/2024
Citius Pharmaceuticals, Inc. today announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas.
-
Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
4/11/2024
Orna Therapeutics today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.
-
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
4/10/2024
Terns Pharmaceuticals, Inc. announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
-
Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhDArtios Strengthens Board of Directors with Appointment of RTW Investments’ Chris Liu, Ph.D.
4/9/2024
Artios Pharma Limited announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.
-
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033
4/3/2024
According to the latest research by Nova One Advisor, the global biotechnology market size was valued at USD 1.54 Trillion in 2023 and is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% from 2024 to 2033
-
Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
4/3/2024
Molecure S.A., a biotechnology company that discovers and develops drugs to the clinical stage and leverages its globally unique expertise in medicinal chemistry and biology to explore and develop first-in-class small-molecule drugs that directly modulate protein activity and mRNA function to treat a range of incurable diseases, has published its 2023 annual report.
-
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
3/28/2024
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the appointment of Colleen Sjogren as Chief Commercial Officer.
-
Nucleus RadioPharma Announces Appointment of Chris McDonald from Kite, a Gilead Company, to Board of Directors
3/27/2024
Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Chris McDonald, Global Head of Technical Operations at Kite, a Gilead Company, to its Board of Directors.
-
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
3/26/2024
Cellares, a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization, announced the addition of Christi Shaw to its Advisory Board.
-
Ubiquitous potential, possible safety advantages and the recent growth of cell and gene therapy are driving investment in a different type of genetic editing.
-
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
3/22/2024
Molecure S.A. has started the clinical trial where OATD-01 is being administered to patients with active pulmonary sarcoidosis as part of a Phase II clinical trial.
-
Immatics Announces Full Year 2023 Financial Results and Corporate Update
3/21/2024
Immatics N.V. provided a business update and reported financial results for the quarter and full year ended December 31, 2023.
-
CAR T-Cell Therapy Market is Rising Rapidly at CAGR 29.8% by 2032
3/15/2024
CAR T-cell therapy is an innovative form of immunotherapy used in the treatment of cancer.
-
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
3/13/2024
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
-
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
3/7/2024
Oxford BioTherapeutics announces significant technological advances to its drug discovery platform OGAP® with a new version to be launched at the 14th Annual World ADC Conference in London named OGAP®-Verify.
-
Tome Biosciences Forms Science and Technology Advisory Committee
3/4/2024
Tome Biosciences, Inc. announces the formation of its Science and Technology Advisory Committee comprised of four leaders in the delivery, development and manufacturing of genomic medicines: David T. Curiel, MD, PhD, Sadik Kassim, PhD, Cynthia Pussinen and Daniel Siegwart, PhD.
-
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
2/28/2024
Arcellx, Inc. (NASDAQ: ACLX) today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.